ENVB

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,901

Underlying: Common Stock · 132,901 shares

Expires 2025-05-26

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F5 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025237 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 691,083

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.

SEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 6

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,658

Underlying: Common Stock · 2,658 shares

Expires 2023-09-16

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F10 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 10,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 5

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 531,602

Underlying: Common Stock · 531,602 shares

Expires 2025-05-26

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F9 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F4 · ownership.nature: Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family.

SEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 4

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,740

Underlying: Common Stock · 79,740 shares

Expires 2025-05-26

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F8 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025625 · ownership.xml · derivative · entry 3

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,675

Underlying: Common Stock · 99,675 shares

Expires 2026-04-05

F5 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F6 · price: Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.

SEC source: 0001493152-21-025625 · ownership.xml · nonDerivative · entry 2

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 531,602

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F3 · price: Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F4 · ownership.nature: Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family.

SEC source: 0001493152-21-025625 · ownership.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,056

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 320,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

SEC source: 0001493152-21-025638 · ownership.xml · derivative · entry 6

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,329

Underlying: Common Stock · 1,329 shares

Expires 2023-09-16

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F10 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 5,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025638 · ownership.xml · derivative · entry 5

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 531,602

Underlying: Common Stock · 531,602 shares

Expires 2025-05-26

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F9 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F4 · ownership.nature: Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family.

SEC source: 0001493152-21-025638 · ownership.xml · derivative · entry 4

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,740

Underlying: Common Stock · 79,740 shares

Expires 2025-05-26

F7 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F8 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025638 · ownership.xml · derivative · entry 3

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,675

Underlying: Common Stock · 99,675 shares

Expires 2026-04-05

F5 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F6 · price: Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.

SEC source: 0001493152-21-025638 · ownership.xml · nonDerivative · entry 2

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 531,602

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F3 · price: Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F4 · ownership.nature: Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family.

SEC source: 0001493152-21-025638 · ownership.xml · nonDerivative · entry 1

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,398

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 310,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

SEC source: 0001493152-21-007899 · ownership.xml · nonDerivative · entry 1

LIND DOUGLAS · CIK 0001181206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,265

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares vested in full on the date of grant.

SEC source: 0001493152-21-005576 · ownership.xml · nonDerivative · entry 1

Van Buiten John · CIK 0001838457 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares shall vest in full on December 31, 2021, if the stock price of the issuer equals or exceeds $4.64, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: Includes 25,000 unvested shares of restricted stock.

SEC source: 0001493152-21-004181 · ownership.xml · nonDerivative · entry 1

Mayer Solomon · CIK 0001533641 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,957

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001493152-21-004178 · ownership.xml · nonDerivative · entry 1

Kegler George A. · CIK 0001761753 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,957

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001493152-21-004176 · ownership.xml · nonDerivative · entry 1

Schabacker Marcus · CIK 0001645282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,957

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001493152-21-004174 · ownership.xml · derivative · entry 2

Johnson David Ian · CIK 0001563432 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,368,999

Underlying: Common Stock · 53,192 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan (the "Plan"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement.

F3 · derivative.exercise_date: The restricted stock units shall vest in tranches based on the achievement of certain Company and individual performance goals in the 2021 calendar year established by the compensation committee of the board of directors of the Company for each such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

F3 · derivative.expiration_date: The restricted stock units shall vest in tranches based on the achievement of certain Company and individual performance goals in the 2021 calendar year established by the compensation committee of the board of directors of the Company for each such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

SEC source: 0001493152-21-004174 · ownership.xml · derivative · entry 1

Johnson David Ian · CIK 0001563432 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,315,807

Underlying: Common Stock · 1,315,807 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan (the "Plan"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement.

F2 · derivative.exercise_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

F2 · derivative.expiration_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

SEC source: 0001493152-21-004172 · ownership.xml · derivative · entry 1

Kanubaddi Avani · CIK 0001838498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 789,484

Underlying: Common Stock · 789,484 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan (the "Plan"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement.

F2 · derivative.exercise_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

F2 · derivative.expiration_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan.

SEC source: 0001140361-19-002484 · form4.xml · nonDerivative · entry 1

Kelton Brent · CIK 0001727392 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,079,953

F1 · price: Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 9

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,250,000

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 8

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,308,850

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 7

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,310,700

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 6

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,317,357

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 5

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,317,557

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 4

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,332,808

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 3

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,346,927

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 2

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,348,442

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000437 · ownership.xml · nonDerivative · entry 1

Sikaria Lokesh · CIK 0001758405 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,349,942

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 9

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,250,000

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 8

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,308,850

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 7

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,310,700

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 6

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,317,357

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 5

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,317,557

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 4

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,332,808

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 3

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,346,927

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 2

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,348,442

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000436 · ownership.xml · nonDerivative · entry 1

Sikaria Chanda · CIK 0001758404 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnote

Disclosed balance after: 2,349,942

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

F2 · ownership.nature: Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012.

F3 · ownership.nature: Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 9

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,250,000

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 8

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,308,850

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 7

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,310,700

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 6

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,317,357

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 5

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,317,557

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 4

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,332,808

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 3

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,346,927

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 2

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,348,442

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.

SEC source: 0001607062-18-000435 · ownership.xml · nonDerivative · entry 1

Lokesh Sikaria Trust Dated 12/14/2012 · CIK 0001758425 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,349,942

F1 · price: The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc.